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Selective counting and sizing of single virus
particles using ﬂuorescent aptamer-based
nanoparticle tracking analysis†
Zoltán Szakács, a Tamás Mészáros, b Marien I. de Jonge c and
Róbert E. Gyurcsányi *a
Detection and counting of single virus particles in liquid samples are largely limited to narrow size dis-
tribution of viruses and puriﬁed formulations. To address these limitations, here we propose a calibration-
free method that enables concurrently the selective recognition, counting and sizing of virus particles as
demonstrated through the detection of human respiratory syncytial virus (RSV), an enveloped virus with a
broad size distribution, in throat swab samples. RSV viruses were selectively labeled through their attach-
ment glycoproteins (G) with ﬂuorescent aptamers, which further enabled their identiﬁcation, sizing and
counting at the single particle level by ﬂuorescent nanoparticle tracking analysis. The proposed approach
seems to be generally applicable to virus detection and quantiﬁcation. Moreover, it could be successfully
applied to detect single RSV particles in swab samples of diagnostic relevance. Since the selective reco-
gnition is associated with the sizing of each detected particle, this method enables to discriminate viral
elements linked to the virus as well as various virus forms and associations.
Introduction
Viruses can be detected either directly or indirectly through
the host immune response (e.g. detection of virus-specific anti-
bodies generated in response to the infection).1 Direct detec-
tion certainly prevails to characterize and standardize virus
preparations, and is also used for medical diagnostics because
it enables genotyping and is more specific than the measure-
ment of host immune responses (e.g. it is not restricted by
seroconversion times, co-morbidities or treatments).1 However,
the majority of direct detection methodologies target only a
single component of the virus, i.e., characteristic nucleic acids
and proteins even though virus pathogenesis involves whole
virus particles.2 Therefore, the interpretation of the results
may be complicated if the detected viral elements are not
linked to intact viral particles but originate from disintegrated
viruses or contaminations. A major step in discriminating
between the free and virus integrated proteins was made by
introducing a dedicated flow cytometry technique3 based on
the concomitant detection of stained viral proteins and
nucleic acids, which increases the likelihood of detecting viral
components integrated in virus particles. However, in this
respect, the most comforting would be if the selective detec-
tion of particular virus components is associated with the size
of the measured entity as well. Virus sizing in the submicron
range has been demonstrated with a wide range of techniques
including electron microscopy,4 atomic force microscopy,5
various light scattering6,7 and interferometric techniques,8
nanoparticle tracking analysis9,10 and resistive pulse
sensing.11–13 These techniques, if used self-standing, are able
to size and in some cases even count viruses in properly puri-
fied samples such as vaccines, but even their excellent size
resolution may not be suﬃcient to unambiguously identify
and quantify viruses in complex biological samples. Therefore,
attempts have been made to combine high resolution sizing
with specific detection of a viral component mainly by anti-
bodies raised against viral coat proteins to selectively detect
virus particles. Techniques capable of detecting and counting
single virus particles in liquids were realized both in hetero-
geneous and homogeneous formats. Thus, surface-immobi-
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lized antibodies could be used to capture viruses in predefined
spots to be consecutively revealed by AFM imaging.5
Alternatively, antibodies were added to the sample to selec-
tively increase the size of the viruses that could be detected by
resistive pulse sensing.14 However, despite the maturity of
single virus detection methodologies, these are still largely
limited to purified virus formulations. Moreover, detection
methods that rely, at least partially, on the size of the particles
mostly target viruses of well-defined size and diﬃculties are
foreseen if applied for viruses that feature an inherently broad
size distribution. Therefore, we were interested to address
these limitations by developing a fluorescent nanoparticle
tracking analysis methodology that enables the selective detec-
tion and counting of single viruses with a broad size
distribution.
Nanoparticle tracking analysis (NTA) was introduced as a
general method to size and count biological and synthetic
nanoparticles in solutions by taking advantage of their light
scattering properties.15–17 The motion of individual nano-
particles is tracked to provide their diﬀusion coeﬃcient which
is further used to calculate their size using the Stokes–Einstein
equation. Furthermore, nanoparticles can be tracked also by
their fluorescence if adequate wavelength excitation lasers and
emission filters are applied. Considering this possibility, we
hypothesized that upon adding fluorescently labeled receptors,
selective for a surface exposed viral protein, the fluorescent
receptor concentration will locally increase around the virus to
a suﬃcient extent to enable its diﬀerentiation from the fluo-
rescent background. Accordingly, the virus particles can be
identified as fluorescent particles, sized and quantified
(Scheme 1). Currently, there is strong interest in synthetic
receptors for viruses as alternatives to antibodies1,18 due to
their better stability and versatility in terms of custom chemi-
cal modification. Therefore, for the fluorescence detection of
virus particles, we took advantage of monovalent fluorescently
labeled aptamers to rule out virus aggregation. For proof of
concept, we used respiratory syncytial virus A2 (RSV), an envel-
oped virus that shows not only a very broad size distribution
(ca. 100–1000 nm)19 but also a variation in shape that includes
spherical and filamentous particles.20 RSV is one of the most
common pathogens to cause lower respiratory tract infections
that aﬀect all age groups but most severely children younger
than 2 years of age as well as elderly and immunocompro-
mised patients. These patients may develop complications and
it was estimated that RSV is responsible for up to 35% of pneu-
monia cases.21 Given the high diagnostic relevance of RSV
detection,22 we explored the application of the single virus
detection methodology in throat swab-based samples.
Experimental section
Chemicals and reagents
DNA aptamers labelled with Alexa Fluor 488 at their 5′-ends
were custom synthesized by Sigma-Aldrich and formulated as
100 µM solutions in pH = 8.0 Tris-EDTA buﬀer. The variable
30-mer nucleotide regions of the RSV aptamers were flanked
by two constant (16-mer) sequences 5′-TAG GGA AG AGA AGG
ACA TAT GAT-30 N- TTGACTAGTACATGACCACTTGA-3′ (TCC
ATA TCG TTT AGC GTA CGG TGG CAG TCT (B10); ACC CGT
CGG ACT CGG CCA TAA ATT AAA GGC (E6); GTG TCC GTT
CTT ATT GGC GGC TCC CAA TGT (E10), TCA TTA GGT GAG
TGT CCG TTC TAC ACT ATA (E11); AGT GCG GTG AGC CGT
CGG ACA TAC AAA TAC (H8)). As a control, a random 76-mer
DNA sequence (randomDNA) was used (5′-ATC CAG AGT GAC
GCA GCA TAT TTC GAC CTT CTA CCT TTG ATT TTT GTG GTC
CTC AGT GTG GAC ACG GTG GCT TAG T-3′). All solutions were
prepared or diluted with a pH = 7.4 phosphate buﬀered saline
(PBS, P4417, Sigma-Aldrich). To prepare solutions for the NTA
experiments, the PBS was filtered through 50 nm pore dia-
meter polycarbonate membranes (Osmonics Inc.). The FITC
labelled anti-respiratory syncytial virus polyclonal antibody
(FITC-antiRSV, ab156657) and the FITC-labeled anti-nucleopro-
tein (FITC-ab25849) were purchased from Abcam. Human rhi-
novirus (HRV) was kindly provided by Kjerstin Lanke
(Department of Medical Microbiology, Radboud Medical
University).
RSV culturing and formulation
For RSV cultivation, RSV A2 infected HeLa cells were used as
described in detail previously.23 The extraction and purifi-
cation of the RSV followed a previously reported standard pro-
cedure.23,24 In brief, the cell suspension was subjected to a
first centrifugation step of 1800g for 10 min to remove the
rough cell debris, followed by ultracentrifugation over a 30%
sucrose layer at 72 000g for 1.5 h. Titration on HeLa cells was
followed by a permeabilization and fixation step using Perm/
Fix buﬀers (Becton Dickinson). The cells were incubated with
FITC-ab25849 for 30 min on ice, washed with Perm/Wash
buﬀers (Becton Dickinson) and measured on a flow-cytometer
(LSR II, Becton Dickinson). The concentration of infectious
particles (plaque forming unit equivalents, PFUe) was deter-
Scheme 1 Schematic of the selective virus sizing and counting by
ﬂuorescent nanoparticle tracking. The RSV containing sample incubated
with the ﬂuorescently labeled aptamer is ﬂown through the thin layer
cell illuminated by a 488 nm laser beam. Using a cut-oﬀ ﬁlter of 495 nm
the scattered light is removed and solely the ﬂuorescently labeled virus
particles are tracked (red lines). The speed of their motion provides the
equivalent diameter of the viruses while the virus count is given by the
average number of virus particles detected in the sensing volume.
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mined as the number of positive cells per volume. For labora-
tory use, RSV A2 was inactivated by incubation with
β-propiolactone (0.025%) under continuous slow shaking at
4 °C for 16 h.25 The excess of the reagent was left to hydrolyse
for 4 h by increasing the temperature to 37 °C and the result-
ing formulation was stored at −80 °C.
Throat swab sample collection
Throat swab samples were taken from healthy volunteers using
medical swab sticks (Meus S.r.L). The swabs were immediately
soaked in 2 mL PBS (pH = 7.4; 1.37 M NaCl, 27 mM KCl,
20 mM KH2PO4, 100 mM Na2HPO4), vortexed, and then centri-
fuged at room temperature (19 060g) for 2 min to transfer the
throat sample from the swab into a centrifuge tube. The col-
lected liquid was stored at −20 °C.
NTA experiments
The NTA experiments were performed using a NanoSight
LM10-HS instrument (Malvern) equipped with a 488 nm laser
light source and a sCMOS camera (Hamamatsu Photonics)
triggered by the laser. In fluorescence mode, a 495 nm cut-oﬀ
filter was used to eliminate the scattered light. Samples of
200–500 μl were flown through the thin layer cell at 6.5 µL
min−1 flow rate using a syringe pump (Harvard Apparatus).
The particle tracks were recorded and analysed using the
NanoSight NTA 2.3 software package. Of note, the NTA soft-
ware automatically corrects the random particle motion with
the unidirectional movement generated by the sample flow.
The particle concentrations were calculated as the average of
either at least 5 one-minute measurements or at least 50 par-
ticle tracks. The throat swab samples were diluted 10-fold and
spiked with various RSV concentrations. The samples were
further centrifuged at 2500g for 15 min to remove large sized
debris and 800 μL aliquots were used for each NTA measure-
ment. The diﬀerent RSV samples, both formulated in PBS and
in diluted throat swab samples, were fluorescently labelled
with 25 nM AlexaFluor488–aptamer conjugates (or 25 nM
FITC-antiRSV antibody) and subjected to NTA detection in
fluorescence mode without separation.
Fluorescence and fluorescence polarization measurements
The fluorescence emission spectra were recorded on a
PerkinElmer LS50B luminescence spectrometer. To this end,
samples were introduced into fluorescence microcuvettes
(105.251 QS Hellma) and excited at 490 nm. A 510 nm cut-oﬀ
filter was used to avoid the detection of scattered light from
the throat swab samples. Fluorescence polarization (FP) experi-
ments were performed using a BioTek Synergy 2 microplate
reader equipped with a xenon flash lamp and a polarizer set
using a 485/20 nm bandpass filter for excitation, a 528/20 nm
bandpass filter for emission and a 510 nm dichroic mirror.
During FP, a plane polarized light is used to excite the fluo-
rescent aptamers with the emitted fluorescent light detected
in the same plane (I∥) and a plane perpendicular to it (I⊥). The
fluorescent aptamer binding to the virus was detected through
an increase in the fluorescence polarization calculated as
FP = (I∥ − I⊥ × G)/(I∥ + I⊥ × G), where G is an instrument
specific correction factor that was determined according to the
instructions of the instrument manufacturer by using 1 nM flu-
orescein solution. FP experiments were performed in 96 well,
flat bottom, black microtiter plates (CLS3694, Corning) blocked
previously with Pierce Protein-Free (TBS) Blocking Buﬀer
(37 570, ThermoFisher Scientific) for 1 h. The sum of volumes
was 60 μl and the fluorescently labelled aptamer concentration
was 0.5 nM in each well. The FP values were reported as the
average of 10 consecutive measurements after the binding
equilibrium was reached (up to 1 h), which was confirmed by
no change in the measured fluorescence intensities.
Results and discussion
Selective fluorescent labelling of RSV particles
Selective fluorescent labelling of RSV can be most straightfor-
wardly achieved by using a fluorescent dye conjugated to a
specific receptor which binds to a viral protein on the virus
envelope. The use of aptamers, besides their robustness and
easy conjugation with fluorescent dyes, was also motivated by
their monovalency. We expected that this will rule out virus
aggregation during their selective labelling. Furthermore, the
ca. an order of magnitude smaller molecular weight of the
aptamers (ca. 22 kDa) than that of conventional antibodies
may lead to larger surface coverage of virus particles and may
thus provide higher sensitivity in this type of application. We
have previously selected and reported a large batch of apta-
mers for RSV with the H8 aptamer exhibiting the best perform-
ance in the proximity based luminescence assay of RSV.24
However, as the suitability of aptamers may depend on a par-
ticular application, we have selected further aptamer candi-
dates for this study. Their relative aﬃnity for RSV was tested
using a competitive fluorescence polarization assay in which
fluorescent aptamer candidates (B4, E6, E10, E11, H8) at a con-
stant concentration of 0.5 nM competed for RSV (1.2 × 105
PFU mL−1) with the unlabelled H8 aptamer. Fluorescence
polarization is a homogeneous assay, i.e., it does not require
the immobilization of the aptamer and the separation of the
free and virus bound aptamer. The fluorescence polarization
scales inversely with the rate at which a fluorescent molecule
rotates. Therefore, the binding of the aptamers to the large
virus particles, which decreases significantly their rotational
rate, can be easily followed through the increased FP.26 The
competitive FP format imposes further stringency to the
binding process minimizing non-specific binding. The
decrease in the fluorescence polarization upon increasing the
unlabelled H8 aptamer concentration indicates the degree of
displacement of the respective fluorescently labelled aptamers
from the RSV, i.e., their relative aﬃnity for RSV.
As can be seen in Fig. 1, aptamers H8 and E10 showed the
highest relative aﬃnity, followed closely by E6 and E11, with
B10 exhibiting significantly poorer performance. Based on this
result, the H8 aptamer was used for most of the follow up
measurements.
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Fluorescence polarization experiments were carried out
to confirm the selective labelling of the RSV virus. Human
rhinovirus, a likely coexisting pathogen in the RSV containing
swab throat samples, was used for this purpose and both virus
formulations were incubated with the AlexaFluor488–H8
aptamer. At low virus concentrations (<106 PFU mL−1) no
association with the HRV could be observed while the binding
to the RSV was detected at almost two orders of magnitude
lower concentrations (Fig. 2A). It is likely that the significant
aptamer binding at higher HRV concentrations is due to the
non-specific electrostatic interaction27,28 between the nega-
tively charged aptamer and positively charged target domains.
This is likely to occur as the homogeneous FP assay lacks a
stringent washing step that would disrupt non-specific inter-
actions. If this scenario applies, adding an unlabelled random
sequence DNA at a suﬃciently large concentration should dis-
place, by competitive action, the aptamer from the HRV. We
found that already a 10-fold excess (5 nM) random DNA back-
ground confirms this hypothesis, i.e. no HRV–aptamer com-
plexes could be detected, while the fluorescent labelling of
RSV was barely aﬀected (Fig. 2B).
Sizing and counting of fluorescently labelled RSV particles
First the RSV virus formulations were investigated in the light
scattering mode by NTA to assess the total number of particles.
As expected, we found a rather broad size distribution, from
ca. 40 nm to 1500 nm equivalent diameter (Fig. S1†) with a
total concentration of (2.4 ± 0.19) × 1011 particles per mL (for
the stock solution). The largest fraction of the detected par-
ticles fell in the 100–200 nm range and tailed towards larger
sizes (Fig. S1†), however, this formulation may still include cell
debris and other membrane or molecular aggregates. To reveal
RSV viruses among these by selective fluorescent labelling, we
used the H8 aptamer that we found earlier to possess the
highest aﬃnity towards attachment glycoprotein (G) of the
RSV.24 The RSV sample (10× diluted stock solution) was incu-
bated for 1 h with 625-fold excess of the aptamer (25 nM) with
respect to the total particle concentration and the counting
was performed in fluorescence mode. To avoid photobleach-
ing, the labelled virus formulations were flown continuously
through the sensing zone to reduce their residence in the laser
beam.
It should be stressed that in contrast to the nanoparticle
tracking analysis of fluorescent particles with “whole volume
fluorescence” (e.g. fluorescent polymer beads) in our case only
the surface of the virus particles is fluorescently labelled. The
challenge is further increased by the fact that after labelling,
the free fluorescent aptamers are not separated from the virus
particles. Such a separation-free detection clearly adds to the
convenience of the method as the separation may aﬀect both
the size and concentration of the virus samples.29 Since the
size of the free fluorescent aptamer is much smaller than the
lower detection limit of NTA in terms of size (∼40 nm for these
types of particles) they cannot be detected as separate fluo-
rescent entities, but only as an increase in the fluorescent
background. In contrast, we expected a significantly higher
local concentration of the fluorescent aptamers binding to the
RSV surface than that of the free aptamer concentration
(Fig. S2B and C†). While accurate surface densities of glyco-
protein G were not reported when considering a 100 nm dia-
meter virus particle and only 100 aptamers per virus that
Fig. 1 Competitive homogeneous FP experiments performed by
keeping the concentration of ﬂuorescently labelled aptamers and that of
the RSV virus constant at 0.5 nM and 1.2 × 105 PFU mL−1, respectively,
while varying the concentration of the unlabelled H8 aptamer. The
curves were normalized with the FP value measured in the absence of
the competing aptamer (FP0).
Fig. 2 Binding of the AlexaFluor488–H8 aptamer (0.5 nM) to RSV and
HRV in the absence (A) and in the presence (B) of randomDNA (10 nM)
followed by FP.
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would amount to a local concentration of fluorescent aptamers
of ca. 320 nM, which is already more than an order of magni-
tude larger than that of the free aptamer. Indeed, while the
unlabelled virus gave no fluorescence signal, the fluorescently
labelled formulation provided clearly detectable fluorescent
particles, i.e., (5.8 ± 0.15) × 109 particles per mL (for the stock
solution). This count however is significantly lower than that
measured in light scattering mode. To rule out that this lower
number of fluorescent particles is caused by any deficiency of
the aptamer binding to the glycoprotein G or lack of these
proteins on some of the viral particles as suggested earlier,19
the same experiment was repeated using fluorescent polyclo-
nal antibodies specific to all RSV viral antigens. The size distri-
bution histograms for both aptamer- and polyclonal antibody-
based fluorescent labeling of virus particles were comfortingly
identical (Fig. 3A).
Owing to the very large heterogeneity of RSV in terms of the
size and packing density of glycoproteins,19 it is diﬃcult to
estimate the number of glycoproteins (G) that need to be satu-
rated by the fluorescent labeled aptamers. Increasing the
aptamer concentration is not a reasonable option because it
also elevates the fluorescent background that makes the fluo-
rescent RSV particle detection diﬃcult. However, by diluting
the virus formulation a close to linear relationship was
obtained between the number of detected virus particles and
the viral concentration expressed in PFU mL−1. At the highest
dilution, the aptamer is ∼3.2 × 106-fold excess in respect of the
virus particles, thus the obtained linear relationship suggests
that suﬃcient aptamers are available throughout the studied
concentration range for the fluorescence visualization of the
virus particles. The number of polyclonal antibody- and
aptamer-labeled virus particles was found to be in excellent
agreement, with the aptamer prevailing in terms of larger
linear range at higher virus concentrations (Fig. 3B).
Thus, after we ruled out contingent deficiencies of the
aptamer binding and virus labelling, the most likely expla-
nation for the much lower particle count in fluorescence than
in light scattering remains that the RSV preparations even
after the purification steps contain a large quantity of cell
debris. This assumption is also supported by the much
smaller concentration of the infectious particles (PFUe) than
the total RSV particles given by the fluorescent counting pro-
viding a particle-to-PFU ratio of 3200. These findings show
clearly the utility and importance of the selective virus count-
ing methodology proposed here in terms of virus standardiz-
ation and characterization.
Detection of RSV in throat swab samples
To investigate the feasibility of the selective detection of RSV
in clinically relevant matrices, throat swab samples collected
from healthy individuals were used. First, it was demonstrated
that the throat swab sample without the virus spiking does not
contain any detectable fluorescent particles and does not
aﬀect the fluorescence of the Alexa488 labelled aptamer
(Fig. S3†). Next, the 10-fold diluted throat swab samples were
spiked with various concentrations of RSV. These samples
were incubated with H8, B10 and E10 aptamers to investigate
the influence of their relative aﬃnity on the fluorescent RSV
count. The results of the fluorescent NTA measurements per-
formed on throat swab samples were compared with RSV
samples formulated solely in PBS (Fig. 4A). We found a close
to linear dependence between the fluorescent RSV count and
the virus concentration for both PBS and throat swab samples
with an insignificant eﬀect of the choice of aptamers on the
sensitivity. Although, the slope of the response in throat swab
samples was ca. 1/3 of that of solely PBS-based formulations,
the results show clearly that RSV particles can be detected
even in complex throat swab samples. Of note, since this
method is capable of detecting single RSV particles, the limit
of detection in terms of concentration is in fact solely deter-
mined by the analysis time, i.e., for smaller concentrations,
larger sample volumes need to be passed through the cell, but
for this proof of concept study we limited the analysis time to
max. 20 min. There is no change in the size distribution of the
RSV viruses detected in the two media (Fig. 4B), which rules
out contingent aggregation or selective loss of a size fraction.
Since the throat swab sample was found to not aﬀect the fluo-
rescence of the aptamers, the most likely reason for the lower
fluorescence RSV count is the competitive displacement of the
aptamers by constituents of the sample matrix, in particular
the DNA background present in physiological samples.
Fig. 3 (A) Size distribution of RSV viruses detected by NTA in ﬂuor-
escence mode after labelling with ﬂuorescent H8 aptamer and poly-
clonal RSV antibody. (B) NTA determined ﬂuorescent RSV concentrations
upon dilution of the RSV formulation.
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This assumption seems to be confirmed by fluorescence polar-
ization assays in which diﬀerent DNA backgrounds were estab-
lished using salmon sperm DNA and the increasing DNA concen-
tration led to decreasing FP values, i.e., removal of the fluorescent
aptamers from RSV (Fig. S4†). The lower number of aptamers
that bind to a virus particle as a result of competitive action of
the sample matrix may reduce the number of detectable RSV par-
ticles, which could explain the sensitivity discrepancy of RSV
determination in “pure” formulations and throat swab samples.
However, even at DNA concentrations as high as 4 µg mL−1 the
aptamer could not be fully displaced from the RSV indicating
clinical applicability of the presented method.
In terms of virus counting, the matrix eﬀect of the throat
swab samples clearly results in a negative bias. Therefore,
while fluorescent nanoparticle tracking analysis is an absolute
method and requires no calibration standards, its direct use
for such sample matrices makes the quantitation of RSV to be
associated with a high level of uncertainty. This problem can
be circumvented if the matrix eﬀect on the RSV count is deter-
mined by standard addition, i.e., after the fluorescent RSV
count is determined in the throat swab sample, the sample is
spiked with RSV standards of known concentrations. The ratio
of the detected and nominal concentration of the RSV stan-
dard can be used as a correction factor to adjust the RSV con-
centration determined in throat swab samples. Given the varia-
bility of the throat swab samples among individuals, this pro-
cedure is best to be applied for each individual throat swab
sample. Table 1 demonstrates that using this standard
addition technique the error in the quantification of RSV in
throat swab samples can be reduced to ca. 25%.
Conclusions
In summary, here we show that single RSV particle detection is
feasible by fluorescent nanoparticle tracking analysis following
their selective labelling with fluorescent aptamers. Given the
size discrimination capability of the method, the detection of
fluorescently labelled RSV could be achieved even without sep-
arating the labelled virus from the free fluorescent aptamer.
Thus this calibration-free counting and sizing method with
little sample preparation is expected to be very appealing for vir-
ologists in terms of virus standardization. Moreover, given the
single species detection ability of the proposed methodology,
the selective detection of RSV was straightforward even in clini-
cally relevant complex samples, such as diluted throat swab
samples. However, the quantification of RSV in throat swab
samples is complicated by a matrix eﬀect (most likely a competi-
tive eﬀect) that results in a reduction of the fluorescent RSV
count. We could circumvent this problem by correcting the
matrix eﬀect using standard addition, but we foresee other pos-
sibilities in terms of improved receptor design. The very promis-
ing results for RSV, which is a diﬃcult target, owing to its het-
erogeneity and variability in size and shape, suggest that the
methodology may be generally applicable for viruses larger than
ca. 80–100 nm. Certainly, the application of this method
requires a suﬃciently low background fluorescence of the
sample matrix for the detection of the virus particles. However,
this may be addressed by using fluorophores and spectral
ranges that minimize the autofluorescence of the sample.
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